Patent ID: 7829573

Claim:
A method for reducing the hypertensive effect of a vascular endothelial growth factor receptor tyrosine kinase inhibitor in a warm-blooded animal to which such inhibitor is being chronically administered as a part of an anti-angiogenic and/or vascular permeability reducing therapy, for the treatment of a disease state selected from cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, autoimmune diseases, acute inflammation, excessive scar formation and adhesions, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal vessel proliferation, said method comprising administering to said animal in combination with said inhibitor an effective amount of an anti-hypertensive agent selected from a calcium channel blocker, an angiotensin II antagonist, an angiotensin converting enzyme inhibitor and a β-blocker, wherein said vascular endothelial growth factor receptor tyrosine kinase inhibitor is selected from: 4-(4-fluoro-2-methylindol-5-yloxy)6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline and 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline, and pharmaceutically acceptable salts thereof; and wherein said calcium channel blocker is selected from: amlodipine; bepridil; clentiazem; diltiazem; fendiline; gallopamil; mibefradil; prenylamine; semotiadil; terodiline; verapamil; aranidipine; barnidipine; benidipine; cilnidipine; efonidipine; elgodipine; felodipine; isradipine; lacidipine; lercanidipine; manidipine; nicardipine; nifedipine; nilvadipine; nimodipine; nisoldipine; nitrendipine; cinnarizine; flunarizine; lidoflazine; lomerizine; bencyclane; etafenone; and perhexiline; and wherein said angiotensin II antagonist is selected from candesartan; eprosartan; irbesartan; losartan; and valsartan; and wherein said angiotensin converting enzyme inhibitor is selected from: alacepril; benazepril; captopril; ceronapril; delapril; enalapril; fosinopril; imidapril; lisinopril; moveltipril; perindopril; quinapril; ramipril; spirapril; temocapril; and trandolapril; and wherein said β-blocker is selected from acebutolol; alprenolol; amosulalol; arotinolol; atenolol; befunolol; betaxolol; bevantolol; bisoprolol; bopindolol; bucumolol; bufetolol; bufuralol; bunitrolol; bupranolal; butidrine hydrochloride; butofilolol; carazolol; carteolol; carvedilol; celiprolol; cetamolol; cloranolol; dilevalol; epanolol; indenolol; labetalol; levobunolol; mepindolol; metipranolol; metoprolol; moprolol; nadolol; nadoxolol; nebivalol; nipradilol; oxprenolol; penbutolol; pindolol; practolol; pronethalol; propranolol; sotalol; sulfinalol; talinolol; tertatolol; tilisolol; timolol; toliprolol and xibenolol.